Physician profile
Erika Smith
NPI 1225441967
$4,454.48
in general payments reported to CMS, 2019-2025
27 companies · $806 in 2025
The $806 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,089 · 2022: $661 · 2023: $626 · 2024: $1,273 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.69 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,103.13 | 2021-2025 | |
| Allergan, INC. | $496.94 | 2021-2022 | |
| Novo Nordisk INC | $410.18 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $278.43 | 2021-2025 | Veozah |
| Amgen INC. | $184.34 | 2021-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $118.22 | 2021-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $84.97 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $72.71 | 2023-2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $71.88 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $60.56 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.93 | 2021-2022 | |
| Amarin Pharma, INC. | $56.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.56 | 2022-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.31 | 2021-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $47.20 | 2021-2025 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.80 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Biohaven Pharmaceuticals, INC. | $40.14 | 2021 | |
| Galderma Laboratories, L.P. | $35.07 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $28.46 | 2021 | |
| Boston Scientific Corporation | $24.81 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Corcept Therapeutics | $22.74 | 2025 | Korlym |
| Jazz Pharmaceuticals INC. | $20.79 | 2021 | |
| Lilly USA, LLC | $19.70 | 2022 | |
| Pfizer INC. | $18.72 | 2021 | |
| Lundbeck LLC | $18.42 | 2023 | Vyepti |
| Paratek Pharmaceuticals, INC. | $16.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.